Drug transporters

Scott Robert Penzak

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Membrane transporters are present in a variety of anatomical locations and organ systems throughout the body. Transporters control the absorption, distribution, intracellular penetration, and excretion of numerous drugs. ATP-binding cassette (ABC) and solute carrier (SLC) superfamilies comprise the majority of clinically relevant transport proteins. In intestinal and liver epithelia, transport proteins control the access of certain medications to systemic circulation. In the kidney, transporters may facilitate or impair drug excretion depending on their specific location and function. However, it is at the blood-brain barrier (BBB) where membrane transporters regulate access of endogenous and exogenous compounds to the central nervous system (CNS). This chapter will review the common drug transport proteins in the intestine and liver as they impact the systemic exposure of drugs that exert their primary pharmacologic effects in the CNS; drug transporters in the kidney that may influence the excretion of such agents will also be addressed. The primary focus of this chapter will be drug transport of centrally acting agents at the BBB, primarily via the efflux transporter and ABCB1 gene product, P-glycoprotein (P-gp). Additional transport proteins will be considered for their documented or putative involvement in drug interactions involving centrally acting medications. Lastly, approaches to circumvent the influence of drug efflux at the BBB will be considered, including modulation of centrally located membrane transporters. Approaches to developing drugs that bypass the effects of efflux transporters at the BBB will also be discussed.

Original languageEnglish
Title of host publicationApplied Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Agents
PublisherSpringer International Publishing
Pages91-119
Number of pages29
ISBN (Electronic)9783319278834
ISBN (Print)9783319278810
DOIs
StatePublished - 1 Jan 2016

Fingerprint

Blood-Brain Barrier
Membrane Transport Proteins
Pharmaceutical Preparations
Carrier Proteins
Central Nervous System Agents
Kidney
Liver
P-Glycoprotein
Intestinal Mucosa
Drug Interactions
Intestines
Central Nervous System
Adenosine Triphosphate
Genes

Keywords

  • ABCB1
  • Analgesia
  • Blood-brain barrier (BBB)
  • Central nervous system (CNS)
  • Depression
  • Drug transport
  • Epilepsy
  • Organic anion transporting polypeptide (OATP)
  • P-glycoprotein (P-gp)
  • Schizophrenia

Cite this

Penzak, S. R. (2016). Drug transporters. In Applied Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Agents (pp. 91-119). Springer International Publishing. https://doi.org/10.1007/978-3-319-27883-4_5
Penzak, Scott Robert. / Drug transporters. Applied Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Agents. Springer International Publishing, 2016. pp. 91-119
@inbook{71d9cb9dfee8413695d71939baeca72e,
title = "Drug transporters",
abstract = "Membrane transporters are present in a variety of anatomical locations and organ systems throughout the body. Transporters control the absorption, distribution, intracellular penetration, and excretion of numerous drugs. ATP-binding cassette (ABC) and solute carrier (SLC) superfamilies comprise the majority of clinically relevant transport proteins. In intestinal and liver epithelia, transport proteins control the access of certain medications to systemic circulation. In the kidney, transporters may facilitate or impair drug excretion depending on their specific location and function. However, it is at the blood-brain barrier (BBB) where membrane transporters regulate access of endogenous and exogenous compounds to the central nervous system (CNS). This chapter will review the common drug transport proteins in the intestine and liver as they impact the systemic exposure of drugs that exert their primary pharmacologic effects in the CNS; drug transporters in the kidney that may influence the excretion of such agents will also be addressed. The primary focus of this chapter will be drug transport of centrally acting agents at the BBB, primarily via the efflux transporter and ABCB1 gene product, P-glycoprotein (P-gp). Additional transport proteins will be considered for their documented or putative involvement in drug interactions involving centrally acting medications. Lastly, approaches to circumvent the influence of drug efflux at the BBB will be considered, including modulation of centrally located membrane transporters. Approaches to developing drugs that bypass the effects of efflux transporters at the BBB will also be discussed.",
keywords = "ABCB1, Analgesia, Blood-brain barrier (BBB), Central nervous system (CNS), Depression, Drug transport, Epilepsy, Organic anion transporting polypeptide (OATP), P-glycoprotein (P-gp), Schizophrenia",
author = "Penzak, {Scott Robert}",
year = "2016",
month = "1",
day = "1",
doi = "10.1007/978-3-319-27883-4_5",
language = "English",
isbn = "9783319278810",
pages = "91--119",
booktitle = "Applied Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Agents",
publisher = "Springer International Publishing",

}

Penzak, SR 2016, Drug transporters. in Applied Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Agents. Springer International Publishing, pp. 91-119. https://doi.org/10.1007/978-3-319-27883-4_5

Drug transporters. / Penzak, Scott Robert.

Applied Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Agents. Springer International Publishing, 2016. p. 91-119.

Research output: Chapter in Book/Report/Conference proceedingChapter

TY - CHAP

T1 - Drug transporters

AU - Penzak, Scott Robert

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Membrane transporters are present in a variety of anatomical locations and organ systems throughout the body. Transporters control the absorption, distribution, intracellular penetration, and excretion of numerous drugs. ATP-binding cassette (ABC) and solute carrier (SLC) superfamilies comprise the majority of clinically relevant transport proteins. In intestinal and liver epithelia, transport proteins control the access of certain medications to systemic circulation. In the kidney, transporters may facilitate or impair drug excretion depending on their specific location and function. However, it is at the blood-brain barrier (BBB) where membrane transporters regulate access of endogenous and exogenous compounds to the central nervous system (CNS). This chapter will review the common drug transport proteins in the intestine and liver as they impact the systemic exposure of drugs that exert their primary pharmacologic effects in the CNS; drug transporters in the kidney that may influence the excretion of such agents will also be addressed. The primary focus of this chapter will be drug transport of centrally acting agents at the BBB, primarily via the efflux transporter and ABCB1 gene product, P-glycoprotein (P-gp). Additional transport proteins will be considered for their documented or putative involvement in drug interactions involving centrally acting medications. Lastly, approaches to circumvent the influence of drug efflux at the BBB will be considered, including modulation of centrally located membrane transporters. Approaches to developing drugs that bypass the effects of efflux transporters at the BBB will also be discussed.

AB - Membrane transporters are present in a variety of anatomical locations and organ systems throughout the body. Transporters control the absorption, distribution, intracellular penetration, and excretion of numerous drugs. ATP-binding cassette (ABC) and solute carrier (SLC) superfamilies comprise the majority of clinically relevant transport proteins. In intestinal and liver epithelia, transport proteins control the access of certain medications to systemic circulation. In the kidney, transporters may facilitate or impair drug excretion depending on their specific location and function. However, it is at the blood-brain barrier (BBB) where membrane transporters regulate access of endogenous and exogenous compounds to the central nervous system (CNS). This chapter will review the common drug transport proteins in the intestine and liver as they impact the systemic exposure of drugs that exert their primary pharmacologic effects in the CNS; drug transporters in the kidney that may influence the excretion of such agents will also be addressed. The primary focus of this chapter will be drug transport of centrally acting agents at the BBB, primarily via the efflux transporter and ABCB1 gene product, P-glycoprotein (P-gp). Additional transport proteins will be considered for their documented or putative involvement in drug interactions involving centrally acting medications. Lastly, approaches to circumvent the influence of drug efflux at the BBB will be considered, including modulation of centrally located membrane transporters. Approaches to developing drugs that bypass the effects of efflux transporters at the BBB will also be discussed.

KW - ABCB1

KW - Analgesia

KW - Blood-brain barrier (BBB)

KW - Central nervous system (CNS)

KW - Depression

KW - Drug transport

KW - Epilepsy

KW - Organic anion transporting polypeptide (OATP)

KW - P-glycoprotein (P-gp)

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=84978221255&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-27883-4_5

DO - 10.1007/978-3-319-27883-4_5

M3 - Chapter

AN - SCOPUS:84978221255

SN - 9783319278810

SP - 91

EP - 119

BT - Applied Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Agents

PB - Springer International Publishing

ER -

Penzak SR. Drug transporters. In Applied Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Agents. Springer International Publishing. 2016. p. 91-119 https://doi.org/10.1007/978-3-319-27883-4_5